ADVANCINGACCESS®

for **SUNLENCA**® (lenacapavir) injection 463.5 mg/1.5 mL



After submitting this form, a dedicated Advancing Access program specialist may reach

PATIENT ENROLLMENT FORM

PHONE: 1-800-226-2056 | FAX: 1-833-445-3234

(Monday through Friday, 9 AM-8 PM EST)

PATIENT CONFIDENTIALITY: Patient confidentiality is of primary importance to us. All patient information will remain confidential. Information may be provided to clinicians, social workers, or family members when required to complete the enrollment process and coordinate patient assistance, and to credit bureaus to determine program eligibility with your consent within this Enrollment Form.

Carto Jestionican Jestia	rough the next steps of	tile process and a	morrer any questions.		CLEAR FORM	
1. REQUESTED PATIENT SUPP	PORT REQUIRED				CHECK ALL BOXES THAT APPLY 🗸	
Benefits Investigation	Co-pay Coupon Program	Prior A	uthorization and Appeals Infor	mation	Patient Assistance Program (PAP)	
2. GILEAD MEDICATION PRES	CRIBED REQUIRE	D				
Product Name: SUNLENCA® (lenacapavir)						
Please indicate if you are requesting inform	mation for: Initial Dose	e (oral/injection) [Maintenance (injection)			
3. PATIENT INFORMATION	REQUIRED					
First Name:	Last	Name:		MI:	Preferred Name:	
Address:			Apt/Unit #:	City:		
State:	ZIP C	Code:	Phone #: () -	-	Preferred Language:	
Email:			Date of Birth: / /		SSN # (Last 4 digits):	
Alternate Contact Name:			Phone #: () -	-	Relationship:	
CONTACT AUTHORIZATION						
that apply): I understand that provide program				do not select a contact preference, nderstand that Advancing Access will ovide program communications to me phone and/or through my healthcare		
when they call. Yes No	ralieu message, including	the hame of my pres	cription, ir i am unavaliable	Yo	xt message and data rates may apply. u can opt out of such text messages at y time by replying "STOP"	
4. INSURANCE INFORMATION	REQUIRED	PL	EASE INCLUDE A COPY OF	THE FRO	NT AND BACK OF INSURANCE CARD(S)	
Patient is uninsured (ie, no health insu	rance through any public	or private payer) — S	SEE OPTIONAL "PATIENT FINA	NCIAL INF	ORMATION" SECTION 5	
Patient is insured (Please fill out all of	the applicable insurance i	nformation below —	Include copy [front & back] of	all insuranc	e cards, including medical and prescription.)	
PRIMARY INSURANCE				ı		
Primary Insurance:		Is	s this a Medicare Part D plan?	Yes	☐ No	
Plan Name:			Insurance Phone #: () –			
Subscriber Name:						
Policyholder Name:			Policyholder Relationship to Patient:			
Policy #:	Group #:	R	x Bin #:		Rx PCN #:	
SECONDARY INSURANCE (Check	this box if patient has se	condary insurance	coverage and include a cop	y [front and	d back] of insurance cards, if available)	
Secondary Insurance:		Is	s this a Medicare Part D plan?	Yes	☐ No	
Plan Name:			Insurance Phone #: () –			
Subscriber Name:						
Policyholder Name:		P	Policyholder Relationship to Pa	tient:		
Policy #:	Group #:	R	x Bin #:		Rx PCN #:	

THIS PAGE TO BE COMPLETED BY **PATIENT** OR **PATIENT'S REPRESENTATIVE** Page **2** of **5**

ADVANCING ACCESS® SUNLENCA® (lenacapavir) PATIENT ENROLLMENT FORM

PHONE: 1-800-226-2056 | FAX: 1-833-445-3234

PATIENT NAME:		DATE OF BIR	тн:	/ /	
5. PATIENT FINANCIAL INFORMATION REQUIRE	D ONLY IF APPLYING FOR THE PATIEN	IT ASSISTANCE PROGRA	M (PAP)		
Current annual household income: \$ (Documental	tion for all sources of income may be requi	ired)			
Number of people in household supported by current annual income	e:	Other:			
ADDITIONAL INSURANCE INFORMATION					
Has the patient applied for the AIDS Drug Assistance Program (ADAI	P)? Yes No If Yes, date of applica	ition:			
What is the ADAP status of the patient? Not applied Pendin	g Wait-listed Denied (include der	nial letter) Not eligible,	reason:		
Is the patient eligible for Medicaid? If No, state reason (if denied, include a copy of the denial letter):	☐ Yes ☐ No	Has the patient applied fo			
Is the patient eligible for Medicare? If No, state reason (if denied, include a copy of the denial letter):	Yes No	Has the patient applied fo			
Is the patient eligible for VA benefits?	☐ Yes ☐ No	If Yes, has the patient tried medication through the V		Yes [] No
Is the patient eligible for an insurance plan offered through a state in marketplace (also known as an exchange)? If No, state reason:		Has the patient applied fo plan offered through a sta marketplace (also known a	te insurance		No
		If Yes, date of application:	/	/	
APPLICANT CONSENT AND DECLARATIONS (R	EQUIRED ONLY IF APPLYING FOR THE	PAP			
By signing below, I certify that all of the information provided in this a	application, including household income, is	complete and accurate.			
I understand that my prescription will be shipped directly to the pres as my agent, to receive my prescription on my behalf. My prescriber, (lenacapavir) will be shipped directly to the HCP.	,				
I understand that program assistance will terminate if Advancing Acc for me. I understand that I may only use the free product received th resale, barter, or trade.				•	
I understand that completing this application does not ensure that I verimbursement or credit for this medication from any insurer, health medication, or any cost for items associated with it, counted as part the application form, modify or discontinue this program, or terminat	plan, or government program. If I am a mer of my out-of-pocket cost for prescription dr	nber of a Medicare Part D p ugs. I understand that the P	lan, I will not se	ek to have thi	is
I authorize the PAP and its administrator to forward my prescription t and income documentation to verify my eligibility into the Patient As: and its third-party administrator to use the information provided o determine my eligibility for the PAP.	sistance Program (eg, identification card, ta	ax return, W-2, last two pay s	stubs, etc). I aut	horize Gilead	ŀ
SIGNATURE OF PATIENT or PATIENT'S AUTHORIZED REPRESENTATIVE UNDER FI	EDERAL OR STATE LAW (REQUIRED):		DATE: /	/	
PATIENT REPRESENTATIVE'S NAME (IF SIGNING FOR THE PATIENT):	PATIENT REPRESENTATIVE'S RELATIONSHIP TO PATI	ENT:	PHONE #:) –	

THIS PAGE TO BE COMPLETED BY PATIENT OR PATIENT'S REPRESENTATIVE

Page **3** of **5**

ADVANCING ACCESS® SUNLENCA® (lenacapavir) PATIENT ENROLLMENT FORM

PHONE: 1-800-226-2056 | FAX: 1-833-445-3234

PATIENT NAME:

DATE OF BIRTH:

6. PATIENT AUTHORIZATION FOR USE AND DISCLOSURE OF PERSONAL HEALTH INFORMATION REQUIRED

Lunderstand that Gilead Sciences, Inc., and its agents, contractors, and other partners ("Gilead") will need to obtain, review, use, and disclose my personal and medical information before I can receive assistance through the Advancing Access program (the "Program") and the Patient Assistance Program ("PAP"). Additional information about how Gilead may use my information can be found at https://www.gilead.com/privacy-statements.

Information to Be Disclosed: My personal information related to my enrollment or participation in the Program, which may include personally identifiable information and Protected Health Information ("PHI") as defined under the Health Insurance Portability and Accountability Act of 1996 ("HIPAA") as amended by the Health Information Technology for Economic and Clinical Health ("HITECH") Act (collectively Personal Information or "PI"):

- General information about me, including my name, birth date, and contact information
- Information about my medical condition, including information about my HIV-related status or treatment with this prescription medication and related medical condition
- Information about my health benefits or health insurance coverage
- Financial information (as necessary), such as my income
- All information provided on this enrollment form and otherwise provided by me to the Program or PAP

Persons Authorized to Disclose and Use My Information: I authorize the following parties to disclose my PI to Gilead and its partners:

- My healthcare providers, including any pharmacy that fills my prescription medication. I understand that my pharmacy providers may receive remuneration for disclosing my PI pursuant to this authorization
- Any health plans, including my health insurance company, or programs that provide me with healthcare benefits

I also authorize Gilead and its partners to redisclose my PI to the following parties:

- My healthcare providers, including the pharmacy that fills my prescription medication
- My health plans, including my health insurance company
- My authorized representative under federal or state law (if applicable)

Purposes for Which My Information May Be Used and Disclosed: My PI may be used and disclosed for the following purposes:

- Completing the enrollment process and verifying the information provided on my enrollment form, including confirming my identity and my use or potential use of the medication prescribed by my healthcare provider
- Establishing my eligibility for benefits from my health plan or other programs
- Providing financial assistance and reimbursement support, if I am eligible, and providing other applicable support, including information on third-party resources that may be able to assist me
- Communicating with my healthcare providers and coordinating my prescription and medication through a pharmacy or healthcare provider's office
- Contacting me to evaluate the effectiveness of the Program and/or the PAP
- Gilead's internal business purposes and audit and compliance purposes
- Confirming my receipt of the prescribed Gilead medication through the PAP based on my communication preferences above
- Deidentifying the information I provide, which means removing elements like my name and address so that I am no longer reasonably identifiable
- Meeting Gilead's legal requirements

Please continue onto next page >>>

THIS PAGE TO BE COMPLETED BY **PATIENT** OR **PATIENT'S REPRESENTATIVE**

Page **4** of **5**

ADVANCING ACCESS® SUNLENCA® (lenacapavir) PATIENT ENROLLMENT FORM

PHONE: 1-800-226-2056 | FAX: 1-833-445-3234

PATIENT NAME: DATE OF BIRTH:

6. PATIENT AUTHORIZATION FOR USE AND DISCLOSURE OF PERSONAL HEALTH INFORMATION (CONTINUED) REQUIRED

Other Important Points:

- I understand that I may choose not to sign this authorization. If I refuse, my eligibility for health plan benefits or ability to obtain treatment from my healthcare providers will not change, but I will not have access to the support offered by the Program and/or the PAP
- Once I sign this Patient Authorization and my PI is transmitted to Gilead and its partners, I understand that state and federal privacy laws may no longer protect or prohibit the redisclosure of the PI disclosed to Gilead and its partners by my healthcare provider or others
- I understand that I am entitled to a copy of this signed authorization and that the authorization expires on the earlier of two (2) years from the date it is signed by me or sooner if required under the laws of the state in which I live
- I understand that I may cancel this authorization at any time by notifying Gilead at 1-800-226-2056. If I cancel, Gilead will stop using this authorization to obtain, use, or disclose my PI after the cancellation date, but the cancellation will not affect uses or disclosures of any PI that have already been made pursuant to this authorization before the cancellation date

Marketing Communications Opt In (OPTIONAL): I would like to receive marketing and informational communications from Gilead related to my medical condition.

PATIEN	NT REPRESENTATIVE'S NAME (IF SIGNING FOR THE PATIENT):	PATIENT REPRESENTATIVE'S RELATIONSHIP TO PATIENT:	PHONE #:)	_		
SIGNATURE OF PATIENT or PATIENT'S AUTHORIZED REPRESENTATIVE UNDER FEDERAL OR STATE LAW (REQUIRED):			DATE:	/	/		
By checking this box, I consent to receive marketing and informational communications from Gilead (as described above) to my phone number provided, including text messages, prerecorded messages and phone calls, which may be sent via autodialer. Text and data rates may apply. I may opt out at any time by texting "STOP."							
	treatment, and/or my prescription medication, including offers, marketing and promotional information, and educational materials, via one or more of the communications methods I agreed to above. I understand that opting in to the marketing and informational communications is not required as a condition of (i) eligibility for health plan benefits or ability to obtain treatment from my healthcare providers, (ii) enrollment in the Program or PAP, or (iii) purchasing any goods or receiving a co-pay or other support from Gilead. The marketing outreach program is separate from the PAP. NOTE: Advancing Access may communicate with me as necessary to administer the Program, including PAP, even if I do not opt in to receive marketing and informational communications from Gilead.						

ADVANCING ACCESS® SUNLENCA® (lenacapavir) PATIENT ENROLLMENT FORM

PHONE: 1-800-226-2056 | FAX: 1-833-445-3234 PATIENT NAME: DATE OF BIRTH: 7. PRESCRIBER INFORMATION REQUIRED MUST BE COMPLETED BY A HEALTHCARE PROVIDER Prescriber Name: Facility Name: State: ZIP Code: Address: City: Phone #: (Office Contact:) Fax #: () State License #: Tax ID #: NPI# 8. DIAGNOSIS/MEDICAL INFORMATION REQUIRED MUST BE COMPLETED BY A HEALTHCARE PROVIDER Diagnosis (Please include ICD code[s]): PLEASE FILL OUT THE BELOW PRESCRIPTION FORM WHICH WILL 9. PRESCRIPTION INFORMATION BE SENT TO THE APPROPRIATE PHARMACY FOR DISPENSING REQUIRED INJECTION MUST BE ADMINISTERED BY HCP Patient First Name: Last Name: Date of Birth: / Is this the patient's first treatment of SUNLENCA (lenacapavir)? Yes No Has the prescription already been sent to the specialty pharmacy? Yes No (If "No," Advancing Access will send this prescription to the specialty pharmacy for processing) Known medication allergies: (☐None) FOR PATIENTS STARTING SUNLENCA, CHOOSE OPTION 1 OR 2 (choose only one option) FOR PATIENTS ON MAINTENANCE SUNLENCA SUNLENCA SUNLENCA Oral 300 mg tablet QUANTITY: 4 | REFILLS: 0 **OPTION 1: INJECTION** sig: Take 2 tablets PO on Day 1, and 2 tablets PO on Day 2 Injection 927 mg SubQ **Oral and Injection** ONLY QUANTITY: 2 x 1.5 mLs | REFILLS: 1 SUNLENCA Injection 927 mg SubQ QUANTITY: 2 x 1.5 mLs | REFILLS: 1 **SIG:** Inject 2 x 1.5 mL subcutaneously sig: Inject 2 x 1.5 mL subcutaneously on Day 1, then repeat every 6 months (26 weeks) every 6 months (26 weeks) SUNLENCA Oral 300 mg tablet QUANTITY: 5 | REFILLS: 0 **OPTION 2:** sig: Take 2 tablets PO on Day 1, 2 tablets PO on Day 2, and 1 tablet PO on Day 8 **Oral and Injection** SUNLENCA Injection 927 mg SubQ QUANTITY: 2 x 1.5 mLs | REFILLS: 1 sig: Inject 2 x 1.5 mL subcutaneously on Day 15, then repeat every 6 months (26 weeks) NOTE: Describer's office REQUIRED Anticipated Start Date: ▶ SUNLENCA injections should be administered in a healthcare setting by a healthcare professional 10. PRESCRIBER CERTIFICATION REQUIRED By signing this form, I certify that I am personally prescribing or furnishing Gilead medication for the patient identified in Section 3. I certify that this prescription medication is medically necessary for the patient and that it will be used as directed. I certify that I will be supervising or coordinating the patient's treatments, in accordance with law, and verify that the information provided as part of my patient's application for the Patient Assistance Program ("PAP") is complete and accurate to the best of my knowledge. I certify that I have not received and shall not seek reimbursement for

any Gilead medication dispensed to the patient through the PAP from any government program or third-party insurer. If applicable, I certify that medication provided to me by the PAP for the eligible patient identified in Section 3 will be provided by me to such patient for his or her own use without charge. I certify that I will not otherwise use any such medication or prescribe, provide, furnish, or dispense all or any portion thereof to any other person or patient. I will notify Gilead if all or any portion of the medication provided to me by the PAP for the patient identified in Section 3 is not prescribed, provided, furnished, or dispensed to that patient, and I will ensure such medication is returned to Gilead or its designated representative, by calling 1-800-226-2056 within 30 days. I certify that I will not sell, resell, offer for sale, trade, or barter medication provided to me under the PAP. Healthcare facility may be subject to audits by Gilead and its third-party audit firm.

I consent that Gilead may perform random audits and verification related to: 1) the applicant identified in Section 3, including but not limited to confirming patient identity and verifying medical necessity; and 2) the dispensing of medication provided to the prescriber through the PAP, including confirming patient receipt of the prescribed Gilead medication and the timely return of any medications received for, but not dispensed to, the patient identified in Section 3, if applicable.

I certify that I have received the appropriate written authorization from the patient, in accordance with the Health Insurance Portability and Accountability Act of 1996, applicable state health information privacy law(s), and any other applicable requirements, in order to release the patient's personal and medical information to Gilead and its agents and contractors for the purposes of assessing the patient's insurance coverage and eligibility for participation in Advancing Access, conducting random audits to verify the information provided on this enrollment form, and for other purposes as outlined in the Patient Authorization For Use and Disclosure of Personal Health Information in Section 6. Gilead is authorized to contact me about the information provided on this form and as needed to facilitate my patient's enrollment and participation in Advancing Access. I understand that Gilead may, if authorized by the patient, contact the patient directly to verify Advancing Access eligibility and updates to insurance coverage, as well as to confirm the receipt of Gilead medication through the PAP.

I understand that completing this enrollment form does not guarantee that assistance will be provided to my patient. My patient has given consent for me to receive their Gilead medication on their behalf. I will receive and secure my patient's medication at my office until it's provided to my patient, when applicable. I will comply with and abide by my state practitioner dispensing laws for authorized prescribers, when applicable.

SPECIAL NOTE: New York prescribers, please submit prescription on an original NY State prescription blank. For all other states, if not faxed, prescription must be on state-specific blank if applicable for your state.

REQUIRED	PRESCRIBER SIGNATURE (DISPENSE AS WRITTEN): NO STAMP ALLOWED		/	/
(SIGN ONE)	PRESCRIBER SIGNATURE (SUBSTITUTIONS ALLOWED): NO STAMP ALLOWED	DATE:	/	/

